Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Gross Profit (2016 - 2025)

Historic Gross Profit for Aytu Biopharma (AYTU) over the last 12 years, with Q4 2025 value amounting to $9.6 million.

  • Aytu Biopharma's Gross Profit fell 1077.32% to $9.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $41.9 million, marking a year-over-year decrease of 523.72%. This contributed to the annual value of $45.8 million for FY2025, which is 657.03% down from last year.
  • As of Q4 2025, Aytu Biopharma's Gross Profit stood at $9.6 million, which was down 1077.32% from $9.2 million recorded in Q3 2025.
  • Aytu Biopharma's Gross Profit's 5-year high stood at $18.6 million during Q2 2023, with a 5-year trough of -$452000.0 in Q1 2021.
  • Moreover, its 5-year median value for Gross Profit was $12.4 million (2021), whereas its average is $12.2 million.
  • Its Gross Profit has fluctuated over the past 5 years, first crashed by 10734.06% in 2021, then skyrocketed by 290663.72% in 2022.
  • Over the past 5 years, Aytu Biopharma's Gross Profit (Quarter) stood at $12.3 million in 2021, then skyrocketed by 40.6% to $17.3 million in 2022, then dropped by 15.56% to $14.6 million in 2023, then fell by 26.14% to $10.8 million in 2024, then dropped by 10.77% to $9.6 million in 2025.
  • Its last three reported values are $9.6 million in Q4 2025, $9.2 million for Q3 2025, and $10.3 million during Q2 2025.